First Manhattan’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-2,000
| Closed | – | – | 1482 |
|
|
2018
Q1 | $0 | Hold |
2,000
| – | – | ﹤0.01% | 1545 |
|
|
2017
Q4 | $2K | Hold |
2,000
| – | – | ﹤0.01% | 1400 |
|
|
2017
Q3 | $4K | Hold |
2,000
| – | – | ﹤0.01% | 1335 |
|
|
2017
Q2 | $5K | Hold |
2,000
| – | – | ﹤0.01% | 1254 |
|
|
2017
Q1 | $6K | Hold |
2,000
| – | – | ﹤0.01% | 1256 |
|
|
2016
Q4 | $3K | Buy |
+2,000
| New | +$4.7K | ﹤0.01% | 1309 |
|
|
2016
Q3 | – | Sell |
-2,000
| Closed | -$8K | – | 1544 |
|
|
2016
Q2 | $8K | Hold |
2,000
| – | – | ﹤0.01% | 1270 |
|
|
2016
Q1 | $11K | Hold |
2,000
| – | – | ﹤0.01% | 1157 |
|
|
2015
Q4 | $34K | Sell |
2,000
-100
| -5% | -$2.38K | ﹤0.01% | 1013 |
|
|
2015
Q3 | $44K | Buy |
2,100
+100
| +5% | +$3.43K | ﹤0.01% | 968 |
|
|
2015
Q2 | $99K | Hold |
2,000
| – | – | ﹤0.01% | 828 |
|
|
2015
Q1 | $156K | Hold |
2,000
| – | – | ﹤0.01% | 742 |
|
|
2014
Q4 | $121K | Buy |
2,000
+1,000
| +100% | +$50.2K | ﹤0.01% | 799 |
|
|
2014
Q3 | $42K | Sell |
1,000
-280,006
| -100% | -$15M | ﹤0.01% | 998 |
|
|
2014
Q2 | $17.4M | Sell |
281,006
-140,000
| -33% | -$8.14M | 0.11% | 131 |
|
|
2014
Q1 | $27.4M | Sell |
421,006
-75,173
| -15% | -$5.08M | 0.18% | 103 |
|
|
2013
Q4 | $27.9M | Sell |
496,179
-28,620
| -5% | -$1.61M | 0.18% | 100 |
|
|
2013
Q3 | $32.2M | Sell |
524,799
-89,365
| -15% | -$6.05M | 0.22% | 79 |
|
|
2013
Q2 | $46.9M | Buy |
+614,164
| New | +$37.8M | 0.32% | 63 |
|
Other funds holding OREX
First Manhattan's OREX Position: Q2 2018 in Review
First Manhattan sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 2,000 shares.
First Manhattan first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $46.9M in Q2 2013. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- First Manhattan reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- First Manhattan sold 2,000 Orexigen Therapeutics, Inc. shares in Q2 2018.
- First Manhattan first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- First Manhattan's Orexigen Therapeutics, Inc. position peaked at $46.9M in Q2 2013.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on First Manhattan's 13F filing for Q2 2018, filed 1 Aug 2018.